Insider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells 24,992 Shares of Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Los Pinos Elisabet De sold 24,992 shares of the firm’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $12.04, for a total transaction of $300,903.68. Following the transaction, the insider now owns 329,847 shares in the company, valued at $3,971,357.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Aura Biosciences Stock Up 14.1 %

NASDAQ AURA traded up $1.45 during midday trading on Friday, hitting $11.74. The company had a trading volume of 1,232,123 shares, compared to its average volume of 174,888. The stock has a market cap of $581.63 million, a price-to-earnings ratio of -6.31 and a beta of 0.37. The firm has a fifty day simple moving average of $8.59 and a two-hundred day simple moving average of $8.03. Aura Biosciences, Inc. has a fifty-two week low of $5.99 and a fifty-two week high of $12.38.

Aura Biosciences (NASDAQ:AURA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.04. As a group, equities analysts predict that Aura Biosciences, Inc. will post -1.7 earnings per share for the current year.

Hedge Funds Weigh In On Aura Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Levin Capital Strategies L.P. lifted its holdings in shares of Aura Biosciences by 194.5% during the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock worth $2,476,000 after acquiring an additional 216,266 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Aura Biosciences by 20.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after acquiring an additional 41,711 shares during the period. American International Group Inc. lifted its holdings in Aura Biosciences by 27.4% during the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after purchasing an additional 3,782 shares during the last quarter. Long Focus Capital Management LLC lifted its holdings in Aura Biosciences by 113.4% during the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after purchasing an additional 561,766 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Aura Biosciences during the 1st quarter valued at about $144,000. 96.75% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on AURA. HC Wainwright raised their target price on shares of Aura Biosciences from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Friday. JMP Securities raised their target price on shares of Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a research note on Friday, September 13th. BTIG Research raised their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Friday. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. Finally, Cowen reiterated a “buy” rating on shares of Aura Biosciences in a research note on Friday. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $23.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.